IL264309A - Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension - Google Patents

Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension

Info

Publication number
IL264309A
IL264309A IL264309A IL26430919A IL264309A IL 264309 A IL264309 A IL 264309A IL 264309 A IL264309 A IL 264309A IL 26430919 A IL26430919 A IL 26430919A IL 264309 A IL264309 A IL 264309A
Authority
IL
Israel
Prior art keywords
grem1
gremlin
antibodies
methods
arterial hypertension
Prior art date
Application number
IL264309A
Other languages
English (en)
Hebrew (he)
Inventor
Dan Chalothorn
Lori C Morton
Original Assignee
Regeneron Pharma
Dan Chalothorn
Lori C Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dan Chalothorn, Lori C Morton filed Critical Regeneron Pharma
Publication of IL264309A publication Critical patent/IL264309A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL264309A 2016-08-29 2019-01-17 Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension IL264309A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380562P 2016-08-29 2016-08-29
PCT/US2017/048137 WO2018044640A1 (en) 2016-08-29 2017-08-23 Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
IL264309A true IL264309A (en) 2019-02-28

Family

ID=59791160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264309A IL264309A (en) 2016-08-29 2019-01-17 Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension

Country Status (12)

Country Link
US (1) US20180057580A1 (https=)
EP (1) EP3504238A1 (https=)
JP (1) JP2019529371A (https=)
KR (1) KR20190040320A (https=)
CN (1) CN109641954A (https=)
AU (1) AU2017320989A1 (https=)
CA (1) CA3031783A1 (https=)
EA (1) EA201990613A1 (https=)
IL (1) IL264309A (https=)
MA (1) MA46046A (https=)
MX (1) MX2019002382A (https=)
WO (1) WO2018044640A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
WO2021257947A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
EP4511395A1 (en) * 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
PE20260306A1 (es) 2023-06-12 2026-02-11 Amgen Inc Proteinas de union a receptor de linfotoxina beta agonistas
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
AU2012350654C1 (en) * 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
ES2733998T3 (es) * 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
ES2898620T3 (es) * 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1

Also Published As

Publication number Publication date
US20180057580A1 (en) 2018-03-01
KR20190040320A (ko) 2019-04-17
MA46046A (fr) 2019-07-03
WO2018044640A1 (en) 2018-03-08
CN109641954A (zh) 2019-04-16
CA3031783A1 (en) 2018-03-08
AU2017320989A1 (en) 2019-02-07
MX2019002382A (es) 2019-06-20
EP3504238A1 (en) 2019-07-03
EA201990613A1 (ru) 2019-07-31
JP2019529371A (ja) 2019-10-17
AU2017320989A9 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL308156B1 (en) Anti-C1S antibodies and methods of using them
IL265800A (en) Anti-lag-3 antibodies and methods of using them
IL264211A (en) Multispecific antigen binding proteins and methods of using them
IL265439A (en) Antibodies against signal-regulatory alpha protein and methods of use
IL267097A (en) Antigen binding proteins against neurophilin and methods of using them
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL261666A (en) Related proteins and methods of using them
IL264309A (en) Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
HUE062927T2 (hu) Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
PT3496739T (pt) Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
IL259681A (en) New antibodies against claudin and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
GB201506380D0 (en) Materials and methods for treatment of pulmonary hypertension
GB201416570D0 (en) Materials and methods for treatment of pulmonary arterial hypertenion